Topical Mitogenic-Activated Protein Kinase (MAPK) Inhibition in Rosacea (TOMIR)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 1
Contacts and Locations
Study Contact
Study Contact
- Name: Leahrut Saavedra, MS
- Phone Number: 518-626-6501
- Email: leahruth.saavedra@va.gov
Study Locations
-
-
New York
-
Albany, New York, United States, 12208
- Samuel S. Stratton VA Medical Center
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Erythematotelangiectatic rosacea diagnosed by a clinician in the centrofacial and/or ocular regions.
Exclusion Criteria:
- Other concurrent diseases for which treatment is being received that would preclude the use of trametinib (i.e., pleural effusion, active infection, intracranial bleeding)
- History of skin allergic reactions or documented allergic reaction to trametinib
- Pregnancy or lactation.
- Heart failure or other heart disease
- Active use of medications with known documented interactions with trametinib (Chloroquine, Ritonavir, Loperamide, Penicillamine)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Single Group Assignment
- Masking: Quadruple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Trametinib
Cheek describing the active compound (topical cream containing 0.1 mg/g trametinib)
|
Topical cream containing 0.1 mg/g trametinib
Other Names:
|
|
Placebo Comparator: Vehicle
Cheek receiving cream without active compound (topical cream lacking active ingredient)
|
Topical cream containing 0.1 mg/g trametinib
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in dermatologic score
Time Frame: 22 days
|
Weekly assessment of skin irritation, using the Organization for Economic Cooperation and Development test for dermal irritation and corrosion.
This test measures cutaneous erythema and edema separately on scales that range from 0 (absence of erythema or edema) to 4 (severe), with higher scores representing worse outcomes.
|
22 days
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Systemic drug absorption
Time Frame: 22 days
|
Blood levels of trametinib will be assessed by high-performance liquid chromatography
|
22 days
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Jacqueline Busingye, MD, Stratton VA Medical Center
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 137506
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.